Incyte CMO Steven H. Stein sells 240,193 shares
The activity comprised 16 option exercises and five separate common-stock sale transactions on the same date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Incyte Corp. (INCY) officer Steven H. Stein, CMO & Head of Late-Stage Dev., exercised options for 240,193 common shares on November 6, 2026, at exercise prices from $61.18 to $113.64, and sold 240,193 shares that day at reported weighted-average prices from $116.0632 to $119.6639. The exercises and sales were made under a Rule 10b5-1 plan.
Insider Trade Summary 10b5-1
Exercise and Sale: 240,193 shares ($8.89M approx. pre-tax spread)
Exercise and Sale
37 txns
Insider
Stein Steven H
Role
CMO & Head of Late-Stage Dev.
Sold
240,193 shs ($28.44M)
Approx. gross sale proceeds
$28.44M
Approx. exercise cost
$19.54M
Approx. pre-tax spread
$8.89M
Share of Position Sold
88.6%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F7 | 8,539 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F8 | 12,335 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F9 | 16,428 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F10 | 15,054 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F11 | 23,526 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F12 | 18,331 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F13 | 19,749 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F14 | 12,305 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F15 | 6,907 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F16 | 16,428 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F17 | 12,743 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F18 | 15,054 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F19 | 24,838 | $0.00 | $0.00 |
| Exercise | Incentive Stock Option (right to buy) F20 | 879 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) F20 | 17,986 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) F21 | 19,091 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,539 | $68.62 | $586K |
| Exercise | Common Stock | 12,335 | $72.27 | $891K |
| Exercise | Common Stock | 16,428 | $80.50 | $1.32M |
| Exercise | Common Stock | 15,054 | $74.78 | $1.13M |
| Exercise | Common Stock | 23,526 | $77.67 | $1.83M |
| Exercise | Common Stock | 18,331 | $61.76 | $1.13M |
| Exercise | Common Stock | 19,749 | $61.18 | $1.21M |
| Exercise | Common Stock | 12,305 | $64.25 | $791K |
| Exercise | Common Stock | 6,907 | $68.25 | $471K |
| Exercise | Common Stock | 16,428 | $85.01 | $1.40M |
| Exercise | Common Stock | 12,743 | $90.56 | $1.15M |
| Exercise | Common Stock | 15,054 | $83.58 | $1.26M |
| Exercise | Common Stock | 24,838 | $83.20 | $2.07M |
| Exercise | Common Stock | 879 | $113.64 | $100K |
| Exercise | Common Stock | 17,986 | $113.64 | $2.04M |
| Exercise | Common Stock | 19,091 | $113.64 | $2.17M |
| Sale | Common Stock F1 | 35,042 | $116.0632 | $4.07M |
| Sale | Common Stock F2 | 22,336 | $117.145 | $2.62M |
| Sale | Common Stock F3 | 60,270 | $118.2729 | $7.13M |
| Sale | Common Stock F4 | 73,969 | $119.1176 | $8.81M |
| Sale | Common Stock F5, F6 | 48,576 | $119.6639 | $5.81M |
Holdings After Transaction:
Employee Stock Option (right to buy) — 64,788 options (Direct);
Incentive Stock Option (right to buy) — 0 options (Direct);
Non-Qualified Stock Option (right to buy) — 0 options (Direct);
Common Stock — 30,916 shares (Direct)
Holdings Before and After:
Employee Stock Option (right to buy), 267,025 to 64,788 options (Direct);
Incentive Stock Option (right to buy), 879 to 0 options (Direct);
Non-Qualified Stock Option (right to buy), 37,077 to 0 options (Direct);
Common Stock, 30,916 to 30,916 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (21)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.56 to $116.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.64 to $117.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.64 to $118.635 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.64 to $119.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.65 to $119.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F6. This includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
- F7. Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F8. Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years.
- F9. Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years.
- F10. Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years.
- F11. Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F12. The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F13. Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
- F14. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F15. The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F16. Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F17. Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years.
- F18. Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F19. Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.
- F20. Beginning January 17, 2017, options become exercisable in full on January 17, 2021.
- F21. Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years.
Key Figures
Options exercised: 240,193 common shares
Exercise price: $61.18-$113.64 per share
Common shares sold: 240,193 shares
+1 more
4 metrics
Options exercised
240,193 common shares
November 6, 2026
Exercise price
$61.18-$113.64 per share
Reported option exercises on November 6, 2026
Common shares sold
240,193 shares
Five transactions on November 6, 2026
Weighted-average sale price
$116.0632-$119.6639 per share
Reported sale transactions on November 6, 2026
Key Terms
weighted average price, Employee Stock Option, Incentive Stock Option, Non-Qualified Stock Option
4 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option financial
"Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Incentive Stock Option financial
"Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
